MFW
ICCC icon

Meristem Family Wealth’s ImmuCell ICCC Stock Holding History

Meristem Family Wealth’s Portfolio ICCC Stock Details ICCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$825K Hold
85,519
– – 0.09% 133
2021
Q4 		$683K Hold
85,519
– – 0.06% 180
2021
Q3 		$790K Buy
+85,519
New +$809K 0.08% 164

Other funds holding ICCC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SRC
Shufro Rose & Co New York $1.47B AUM 19.38% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OMC
Overbrook Management Corp New York $663M AUM 35.04% 1-Year Est. Return
PCM
Perritt Capital Management Chicago, Illinois $59.8M AUM 26.94% 1-Year Est. Return
SFS
Strategic Financial Services Utica, New York $2.1B AUM 19.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Meristem Family Wealth's ICCC Position: Q1 2022 in Review

Meristem Family Wealth held its ImmuCell (ICCC) position steady in Q1 2022 at 85,519 shares worth $825K. The position accounts for 0.09% of the portfolio, ranked #133.

Meristem Family Wealth first reported a position in ICCC in Q3 2021 and has held it in 3 quarters since. 27 funds tracked by Wall St. Rank hold ICCC as of Q1 2022.

  • Meristem Family Wealth held 85,519 shares of ImmuCell worth $825K as of Q1 2022.
  • Meristem Family Wealth left its ImmuCell share count unchanged in Q1 2022.
  • ImmuCell made up 0.09% of Meristem Family Wealth's portfolio in Q1 2022, its #133 holding.
  • Meristem Family Wealth first reported a position in ImmuCell in Q3 2021 and has held it in 3 quarters since.
  • 27 funds tracked by Wall St. Rank held ImmuCell as of Q1 2022.

Based on Meristem Family Wealth's 13F filing for Q1 2022, filed 11 May 2022.